Intelligent Bio Solutions (Intelligent Bio Solutions) Cash And Cash Equivalents : $9.40 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Intelligent Bio Solutions Cash And Cash Equivalents?

Intelligent Bio Solutions's quarterly cash and cash equivalents increased from Sep. 2023 ($0.19 Mil) to Dec. 2023 ($1.12 Mil) and increased from Dec. 2023 ($1.12 Mil) to Mar. 2024 ($9.40 Mil).

Intelligent Bio Solutions's annual cash and cash equivalents declined from Jun. 2021 ($12.57 Mil) to Jun. 2022 ($8.24 Mil) and declined from Jun. 2022 ($8.24 Mil) to Jun. 2023 ($1.54 Mil).

Intelligent Bio Solutions Cash And Cash Equivalents Historical Data

The historical data trend for Intelligent Bio Solutions's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intelligent Bio Solutions Cash And Cash Equivalents Chart

Intelligent Bio Solutions Annual Data

Trend

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Cash And Cash Equivalents

Get a 7-Day Free Trial

0.20

0.43

12.57

8.24

1.54

Intelligent Bio Solutions Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash And Cash Equivalents	Get a 7-Day Free Trial															2.28	1.54	0.19	1.12	9.40

Intelligent Bio Solutions Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Intelligent Bio Solutions (NAS:INBS) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Intelligent Bio Solutions Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Intelligent Bio Solutions's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Intelligent Bio Solutions (Intelligent Bio Solutions) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Intelligent Bio Solutions Inc (NAS:INBS) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

12Q:Germany

Address

57th Street, 142 West, 11th Floor, New York, NY, USA, 10019

Website

https://www.gbs.inc

Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana.

Executives

Harry Simeonidis	director, officer: CEO, President	708 THIRD AVENUE, 6TH FLOOR, NEW YORK CITY NY 10017
Foundation Ma-ran	10 percent owner	1908 CLIFF VALLEY WAY NE, ATLANTA GA 30329
Gary W. Rollins Foundation	10 percent owner	1908 CLIFF VALLEY WAY NE, ATLANTA GA 30329
David A Jenkins	director	P.O. BOX 682838, PARK CITY UT 84068
Jason Isenberg	director	1908 CLIFF VALLEY WAY NE, ATLANTA GA 30329
Spiro Kevin Sakiris	officer: Chief Financial Officer	708 THIRD AVENUE, 6TH FLOOR, NEW YORK CITY NY 10017
Life Science Biosensor Diagnostics Pty Ltd	10 percent owner	LEVEL 9, 85 CASTLEREAGH STREET, SYDNEY C3 2000
Tom Parmakellis	director	708 THIRD AVENUE, 6TH FLOOR, NEW YORK CITY NY 10017
Victoria Gavrilenko	director	708 THIRD AVENUE,, 6TH FLOOR, NEW YORK CITY NY 10017
Christopher Towers	director	1981 MARCUS AVENUE, SUITE 130, LAKE SUCCESS NY 11042
Lawrence B Fisher	director	C/0 FINANCIAL FEDERAL CORP, 733 THIRD AVENUE, NEW YORK NY 10017
Leonard Victor Kempler	director	708 THIRD AVENUE,, 6TH FLOOR, NEW YORK CITY NY 10017
George Margelis	director	708 THIRD AVENUE, 6TH FLOOR, NEW YORK CITY NY 10017
Boyages Steven Constantine	director	708 THIRD AVENUE,, 6TH FLOOR, NEW YORK CITY NY 10017
Jonathan Scott Hurd	director	708 THIRD AVENUE,, 6TH FLOOR, NEW YORK CITY NY 10017